881683-81-4

Basic information

• Product Name: (S)-ethyl 2-(tert-butoxycarbonylamino)non-8-enoate
• Synonyms: (S)-ethyl 2-(tert-butoxycarbonylamino)non-8-enoate;(2S)-2-[[(tert-Butoxy)carbonyl]amino]-8-nonenoic acid ethyl ester;8-Nonenoic acid, 2-[[(1,1-diMethylethoxy)carbonyl]aMino]-, ethyl ester, (2S)-;ethyl (S)-2-((tert-butoxycarbonyl)amino)non-8-enoate
• CAS NO: 881683-81-4
• Molecular Formula: C16H29NO4
• Molecular Weight: 299.41
• Mol File: 881683-81-4.mol

Chemical Properties

• Boiling Point: 395.1±42.0 °C(Predicted)
• Appearance: /
• Density: 0.985
• PKA: 11.27±0.46(Predicted)
• CAS DataBase Reference: (S)-ethyl 2-(tert-butoxycarbonylamino)non-8-enoate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-ethyl 2-(tert-butoxycarbonylamino)non-8-enoate(881683-81-4)
• EPA Substance Registry System: (S)-ethyl 2-(tert-butoxycarbonylamino)non-8-enoate(881683-81-4)

Safety Data

• Hazardous Substances Data: 881683-81-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(S)-ethyl 2-(tert-butoxycarbonylamino)non-8-enoate is used as a building block for creating more complex organic molecules, particularly in the field of medicinal chemistry. Its stability and ease of manipulation during chemical reactions make it a valuable component in the synthesis of a wide range of compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (S)-ethyl 2-(tert-butoxycarbonylamino)non-8-enoate is used as a key intermediate in the preparation of peptides and other bioactive molecules. The Boc protecting group allows for controlled deprotection and functionalization, facilitating the synthesis of targeted therapeutic agents.
Used in Research and Development:
(S)-ethyl 2-(tert-butoxycarbonylamino)non-8-enoate is also utilized in research and development for the exploration of new chemical reactions and the design of novel bioactive compounds. Its unique structure and functional groups make it an attractive candidate for studying various reaction mechanisms and developing innovative synthetic strategies.

Upstream product

• 881683-80-3 ethyl (2R)-N-Boc-2-amino-5-oxo-non-8-enoate 
• 1009637-39-1 2-tert-butoxycarbonylamino-8-nonenoic acid ethyl ester 
• 881683-80-3 ethyl (2S)-N-Boc-2-amino-5-oxo-non-8-enoate 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 
• 1009637-55-1 C₁₇H₂₉NO₆ 

Downstream Products

• 881683-84-7 (2R)-2-({[(1,1-dimethylethyl)oxy]carbonyl}amino)-8-nonenoic acid 
• 300831-21-4 (S)-2-(tert-butoxycarbonylamino)non-8-enoic acid 
• 769167-55-7 (S)-2-cyclopentyloxycarbonyl-amino-8-nonenoic acid 

Relevant articles and documents

CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF

The present technology relates to compounds, kits, compositions, and methods useful for the treatment of fibrotic disease. In some aspects, the present technology provides for treatment of various diseases or disorders associated or mediated, at least in part, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is generally applicable to compounds which inhibit myofibroblast differentiation.

A concise synthesis of the HCV protease inhibitor BILN 2061 and its P3 modified analogs

A concise synthesis of BILN 2061 was achieved through more efficient installation of P2 4-quinoline moiety via SN2 displacement of the β-OBs group located on the 4-hydroxyl proline intermediate, which was prepared from 4-α-hydroxyl proline analog via Mitsunobu reaction with inversion of stereochemistry. In addition, a short and practical synthesis for P3 unit is also described herein. Final assembly of four fragments for BILN 2061 was achieved with an overall yield of 58% in 4 steps from P1 to 15a. Furthermore several analogs of BILN 2061 (WX-1-WX-5) containing modifications on P3 unit were synthesized successfully using the same synthetic route as described for the parent inhibitor BILN 2061. Copyright

Interaction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides

Inhibitors of histone deacetylases (HDACs) are a promising class of anticancer agents that effect gene regulation. To know the interaction of aliphatic cap groups with HDACs, cyclic tetrapeptide and bicyclic peptide disulfide hybrids were synthesized without aromatic ring in their macrocyclic framework. Benzene ring of l-Phe in chlamydocin was replaced with several aliphatic amino acids and also a fused bicyclic tetrapeptide was synthesized by ring closing metathesis using Grubb's first generation catalyst. The inhibitory activities of the cyclic peptides against histone deacetylase enzymes were evaluated, which demonstrated most of them are interesting candidates as anticancer agents.

A NOVEL PROCESS FOR THE PREPARATION OF NONRACEMIC LONG CHAIN α-AMINO ACIDS DERIVATIVES

The present invention provides a process for the preparation of a nonracemic a-amino acid derivative from an optically active N-acyl lactam using an organometallic reagent to effect the opening of the ring followed by reduction of the ketone carbonyl to an alcohol or a methylene, or by a reductive amination to an amine, or by a ketalization reaction.